Drug Trial Radar · NCT07375758
A Study of MIL116 in Healthy Participants and Patients With IgA Nephropathy.
Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
130
Planned (sponsor's estimate)
Start
Feb 5, 2026
Primary completion
Jun 2028
Study completion Jun 2029
Sponsor
- Lead sponsor
- Beijing Mabworks Biotech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase I/II study designed to evaluate the safety, tolerability, PK and PD of subcutaneous MIL116, an anti-APRIL monoclonal antibody, in healthy participants and patients with IgA Nephropathy.
Conditions
- Immunoglobulin A Nephropathy
Interventions
MIL116Drug
MIL116 is supplied as sterile solution for subcutaneous (SC) injection.
Matching PlaceboDrug
Placebo is to be administered at a matching volume by SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase Ia: Safety and Tolerability of Single Ascending Doses of MIL116 in Healthy Participants.Time frame: up to 6 months after enrollment
- Phase Ib: Safety and Tolerability of Multiple-Ascending Doses of MIL116 in IgAN Participants.Time frame: up to 18 months after enrollment
- Phase II: Change in Gd-IgA1 from Baseline at Week 12Time frame: up to 18 months after enrollment
- Change in 24-Hour Urine UPCR from Baseline at Week 24Time frame: up to 18 months after enrollment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.